In Waldenström macroglobulinaemia, and less often in myeloma, an abnormal antibody protein can build up until the blood is too thick to flow through small vessels. Warning signs are nosebleeds or bleeding gums that will not stop, blurred or lost vision, headache, dizziness or drowsiness. It is an emergency: a machine removes and replaces the plasma (plasma exchange), then the cancer is treated.
Hyperviscosity syndrome (HVS) is a clinical diagnosis (BSH 2022): mucosal bleeding, visual disturbance and neurological symptoms in someone with a high paraprotein. ASFA 2026 puts it in 10% to 30% of people with Waldenström macroglobulinaemia and 2% to 6% with myeloma (typically IgA or IgG3). In two retrospective cohorts it occurred in 14% of 825 and 13% of 997 patients with Waldenström macroglobulinaemia and did not change overall survival. Fundoscopy is part of the assessment: retinal changes can be present without visual symptoms and are themselves a reason to treat (Gertz 2018, Weaver 2020). Plasma exchange is not held for a viscosity result (Gertz 2018).
The guidelines read agree on plasma exchange for symptomatic HVS. ASFA puts it in category I (accepted first-line therapy) with grade 1B, a strong recommendation on moderate-quality evidence, and counts no randomised trial behind it (3 controlled trials and more than 10 case series). BSH gives Grade A1, calling hyperviscosity a haematological emergency and also an indication for definitive treatment. The Mayo mSMART guideline (2016) says exchange should be promptly initiated before cytoreductive therapy (level 3, grade B). ASFA: 1 to 1.5 total plasma volumes, daily or every other day, albumin or plasma replacement, generally 1 to 3 procedures, with viscosity and immunoglobulin monitored; IgG is less intravascular than IgM, so 4 to 5 exchanges may be needed, with fluid shifts after the procedure. Exchange does not treat the disease: ASFA says IgM returns to baseline about 3 to 5 weeks later, so systemic treatment follows.
The sources differ on three points. Viscosity threshold: ASFA says most patients are symptomatic at 6 to 7 cp and that HVS can occur above 4 cP; BSH says it should be considered above 3 mPas, citing a series in which about half of 85 symptomatic patients were below 4 mPas; Gertz says no level can be specified for exchange without symptoms. Rituximab IgM flare: ASFA (category I, grade 1C, from 3 case series and 3 case reports) says to consider exchange first when viscosity is above 3.5 cp or IgM above 4 g/dL (40 g/L), or else to hold rituximab for 1 to 3 cycles; BSH (Grade C1) says to defer rituximab or perform prophylactic plasmapheresis when IgM is above 40 g/L; mSMART (level 3, grade A) says rituximab alone is best avoided at a very high IgM without pre-emptive plasmapheresis, and names no figure; Gertz calls pre-emptive exchange unproven against close monitoring. Whether an IgM above 60 g/L alone should start treatment: one cohort says yes, another no (variants).
On red cell transfusion before viscosity is lowered, Weaver 2020 says to take caution to avoid excessive red cell or platelet transfusion, and Gertz 2018 says a theoretical argument could be made to withhold transfusion in haemodynamically stable patients while stating there is no scientific proof; neither ASFA nor BSH mentions it. The reader's own haematology team's protocol comes first; this page is for understanding the care, not for directing it.
Why: These three kinds of symptom are how thick blood shows itself, and nosebleeds that keep coming back are often treated several times before anyone checks the blood.
“The classic triad of hyperviscosity includes mucosal bleeding, visual abnormalities, and neurological abnormalities.”
Why: Treatment stops it getting worse (ASFA). The serious forms include bleeding in the brain and a blocked vein at the back of the eye, which can cost sight for good (Gertz, Weaver). No source read sets a time limit in hours.
“Hyperviscosity is a haematological emergency and is an indication for therapeutic plasma exchange.”
British Society for Haematology (British Journal of Haematology, Pratt, El-Sharkawi et al.) 2022 · Grade A1
Why: Bleeding in the retina can be present before sight is affected, and retinal changes caused by hyperviscosity are themselves a reason to treat.
“Whenever HVS is suspected, ophthalmoscopy should be performed.”
Why: No single viscosity number separates people with symptoms from people without, so the picture in front of the doctor decides.
“The diagnosis of HVS remains a clinical one.”
British Society for Haematology (British Journal of Haematology, Pratt, El-Sharkawi et al.) 2022
Why: The test can take time to come back, and the treatment is what stops the bleeding and protects sight.
“Plasma exchange should not be delayed awaiting viscosity results, but a sample should be sent for confirmation of the clinical impression.”
Why: Plasma exchange removes the protein that is thickening the blood and eases symptoms quickly; it does nothing to the cells that make the protein.
“The recommended treatment approach is TPE followed by systemic treatment.”
American Society for Apheresis (Journal of Clinical Apheresis, Zantek et al.) 2026 · Category I, Grade 1B
Why: The machine has to draw and return blood quickly, which small veins in the arm often cannot support.
“Central line placement is used to allow adequate blood flow.”
Frontiers in Oncology (Weaver, Rubinstein and Cornell; narrative review) 2020
Why: Most of the IgM protein is inside the blood vessels, so one to three sessions are usually enough in Waldenström macroglobulinaemia.
“Daily or every other day TPE should be done until acute symptoms abate (generally 1–3 procedures).”
American Society for Apheresis (Journal of Clinical Apheresis, Zantek et al.) 2026 · Category I, Grade 1B
Why: The number of sessions is set by how the person responds, not fixed in advance.
“Clinical monitoring of viscosity and IgM or IgG levels is recommended during treatment to determine if subsequent TPE procedures are necessary.”
American Society for Apheresis (Journal of Clinical Apheresis, Zantek et al.) 2026
Why: ASFA puts 45% to 65% of IgG inside the blood vessels, against 75% to 80% of IgM, so one exchange removes a smaller share of it. Because of the IgG outside the vessels, significant fluid shifts may occur at the end of a procedure or shortly after it.
“In IgG‐associated HVS, IgG is 45%–65% intravascular. Therefore, 4–5 TPE may be needed.”
American Society for Apheresis (Journal of Clinical Apheresis, Zantek et al.) 2026
Why: Added red cells change how the blood flows, and the anaemia may be partly dilution from expanded plasma. This rests on reasoning, not trials: Gertz writes that a theoretical argument could be made to withhold transfusion in a stable patient and that there is no scientific proof for it.
“Caution should be taken to avoid excessive packed red blood cell or platelet transfusions until TPE has successfully reduced hyperviscosity”
Frontiers in Oncology (Weaver, Rubinstein and Cornell; narrative review) 2020
Why: Exchange does not affect the disease itself: ASFA says the IgM is back at its starting level about 3 to 5 weeks later.
“For this reason, following TPE, it is important to initiate definitive systemic treatment (chemotherapy and/or immunotherapy).”
American Society for Apheresis (Journal of Clinical Apheresis, Zantek et al.) 2026
Why: Rituximab can push the IgM up for a time before it brings it down (the IgM flare), which can tip a person with a high level into hyperviscosity.
“The introduction of rituximab should be deferred (or prophylactic plasmapheresis performed) in patients considered at a higher risk of hyperviscosity, this being defined by an IgM/ M-protein >40 g/L”
British Society for Haematology (British Journal of Haematology, Pratt, El-Sharkawi et al.) 2022 · Grade C1
Why: BSH asks for this in all patients, not only those with a high IgM. The Eastern Cooperative Oncology Group study (Ghobrial 2004) could not identify factors that predicted a rise.
“Given the risk of IgM flare, careful monitoring of all patients receiving rituximab is required with monitoring of sequential IgM levels, clinical assessment for hyperviscosity syndrome (HVS) and monitoring of plasma viscosity if available”
British Society for Haematology (British Journal of Haematology, Pratt, El-Sharkawi et al.) 2022 · Grade A1
Why: The first signs happen at home, and a nosebleed or blurred sight is easy to put down to something else.
Common practice: No source read states patient teaching as a recommendation. All of them rest on early recognition: ASFA writes that symptomatic HVS 'requires prompt recognition and intervention', and Gertz describes patients sent home repeatedly after cautery for nosebleeds before a blood count was taken.
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
For hyperviscosity with symptoms, the guidelines read agree on therapeutic plasma exchange: ASFA 2026 category I (accepted first-line therapy), grade 1B (strong recommendation, moderate-quality evidence); BSH 2022 Grade A1, as a haematological emergency; Mayo mSMART 2016 level 3, grade B, promptly and before cytoreductive therapy. ASFA gives the schedule: 1 to 1.5 plasma volumes daily or every other day until symptoms settle, generally 1 to 3 procedures, followed by systemic treatment because exchange does not treat the disease. No randomised trial supports this: ASFA counts 3 controlled trials and more than 10 case series. The diagnosis is clinical, the retina is examined, and exchange is not delayed for a viscosity result (Gertz 2018). On preventing a rituximab IgM flare the positions differ. ASFA (category I, grade 1C) says plasma exchange should be considered before rituximab when viscosity is above 3.5 cp or IgM above 4 g/dL, or rituximab held for 1 to 3 cycles until IgM is below 4 g/dL. BSH (Grade C1) says to defer rituximab or perform prophylactic plasmapheresis when IgM or M-protein is above 40 g/L, and to monitor everyone given rituximab (Grade A1). mSMART (level 3, grade A) says rituximab alone is contraindicated in symptomatic hyperviscosity and, without pre-emptive plasmapheresis, best avoided at a very high IgM. Gertz 2018 says pre-emptive exchange is unproven against close monitoring and that a flare from below 4000 mg/dL is unlikely to cause symptoms. On the viscosity at which to think of the syndrome, ASFA says most patients have symptoms at 6 to 7 cp, BSH says to consider it above 3 mPas, and Gertz says no threshold applies to everyone. Caution with red cell transfusion until viscosity is lowered comes from two reviews and is, in Gertz's words, without scientific proof; neither ASFA nor BSH addresses it.
American Society for Apheresis (Journal of Clinical Apheresis, Zantek et al.) 2026 · British Society for Haematology (British Journal of Haematology, Pratt, El-Sharkawi et al.) 2022 · JAMA Oncology (Kapoor et al., Mayo Clinic; read as the author manuscript on PubMed Central, supplement not read) 2017 · Blood (Gertz, Mayo Clinic; narrative review, the author declares personal fees from drug companies outside the work) 2018 · Frontiers in Oncology (Weaver, Rubinstein and Cornell; narrative review) 2020
Where it differs: Three approaches are in use for a person with a high IgM who needs a rituximab regimen. Plasma exchange before the first rituximab dose: ASFA says "Prophylactic TPE is performed to lower IgM to < 4 g/dL prior to rituximab therapy." Leaving rituximab out of the first cycles: ASFA says rituximab can be held at first, with the chemotherapy component given for 1 to 3 cycles until the serum IgM is below 4 g/dL, and BSH allows either route above 40 g/L. The Mayo mSMART guideline sets no figure: rituximab alone is contraindicated in symptomatic hyperviscosity and, without pre-emptive plasmapheresis, "is best avoided in patients with very high serum IgM". Close monitoring with treatment only if symptoms develop, which Gertz describes as the comparator that pre-emptive exchange has not been shown to beat.
Evidence: No trial compares them. ASFA grades prophylactic exchange 1C on 3 case series and 3 case reports; BSH grades its recommendation C1; mSMART grades its own level 3, grade A. Gertz: "It is unproven that preemptive plasma exchange in asymptomatic patients with IgM levels >5000 prevent complications when compared with close monitoring following rituximab and the initiation of treatment if symptoms develop." How often a flare happens also differs by source: ASFA says 30% to 70% of patients within 4 weeks of starting rituximab; Gertz says 22%; in an Eastern Cooperative Oncology Group study of rituximab alone, IgM rose in 29 of 54 patients (54%) and was still raised at 4 months in 4 of 15, and no predicting factor was found.
American Society for Apheresis (Journal of Clinical Apheresis, Zantek et al.) 2026 · British Society for Haematology (British Journal of Haematology, Pratt, El-Sharkawi et al.) 2022 · JAMA Oncology (Kapoor et al., Mayo Clinic; read as the author manuscript on PubMed Central, supplement not read) 2017 · Blood (Gertz, Mayo Clinic; narrative review, the author declares personal fees from drug companies outside the work) 2018 · Cancer (Ghobrial et al.) 2004
Where it differs: ASFA: the syndrome can occur when IgM exceeds 4 g/dL and relative plasma viscosity exceeds 4 cP, and most patients are symptomatic at 6 to 7 cp. BSH: it should be considered above 3 mPas, and hyperviscosity rarely occurs with a paraprotein below 30 g/L. Gertz: each patient has their own threshold, so no viscosity level can be named above which people without symptoms should have prophylactic exchange, and "Asymptomatic patients with an elevation in the serum viscosity do not require plasma exchange". ASFA does describe exchange for retinal changes in people otherwise free of symptoms.
Evidence: Retrospective series. BSH cites a study in which about half of 85 patients with symptomatic hyperviscosity had a serum viscosity under 4 mPas. ASFA notes that viscosity does not consistently match symptoms between patients but that the level at which symptoms appear is generally reproducible in the same patient.
American Society for Apheresis (Journal of Clinical Apheresis, Zantek et al.) 2026 · British Society for Haematology (British Journal of Haematology, Pratt, El-Sharkawi et al.) 2022 · Blood (Gertz, Mayo Clinic; narrative review, the author declares personal fees from drug companies outside the work) 2018
Where it differs: Some centres start treatment of Waldenström macroglobulinaemia when IgM is above 60 g/L (6000 mg/dL) even without symptoms, to head off hyperviscosity; others observe.
Evidence: Two retrospective cohorts point in opposite directions. Dana-Farber (Gustine 2017, 825 patients, 113 with symptomatic hyperviscosity): an IgM above 60 g/L at diagnosis was associated with a median of 3 months to symptomatic hyperviscosity, and the authors support it as a criterion to start therapy. Mayo Clinic (Abeykoon 2018, 997 patients, 130 with symptomatic hyperviscosity): of 13 people with smouldering disease and IgM above 6000 mg/dL who were observed, 15% later developed hyperviscosity symptoms and the median time to first therapy was 6.9 years; serum viscosity at diagnosis, not IgM, was the independent predictor, and the authors conclude such patients can be safely observed. In both cohorts hyperviscosity did not change overall survival.
British Journal of Haematology (Gustine et al., Dana-Farber Cancer Institute) 2017 · American Journal of Hematology (Abeykoon et al., Mayo Clinic) 2018
Where it differs: Plasma is separated and then passed through a second filter that holds back large proteins such as IgM and returns albumin, so less replacement fluid is needed. Gertz reports it is used mainly in Japan and is not approved in the United States.
Evidence: ASFA: "Cascade filtration and membrane filtration techniques have been described and may have similar efficacy in removing M‐protein." Gertz cites a single-centre report of 260 procedures, 61% centrifugal and 39% double filtration, with similar reduction in viscosity and the same rate of adverse reactions.
American Society for Apheresis (Journal of Clinical Apheresis, Zantek et al.) 2026 · Blood (Gertz, Mayo Clinic; narrative review, the author declares personal fees from drug companies outside the work) 2018
Where it differs: Repeated exchange every 1 to 4 weeks, guided by symptoms or retinal changes, to keep a person below the level at which their own symptoms appear, either while chemotherapy is being started or where it cannot be given. ASFA: "Pregnant patients and those who are unable to receive systemic therapy may be candidates for maintenance TPE."
Evidence: Described in the ASFA fact sheet without a separate grade. It holds the protein down while it lasts and does not treat the disease.
American Society for Apheresis (Journal of Clinical Apheresis, Zantek et al.) 2026
Where it differs: For a person with a raised viscosity, a reason to treat and no symptoms, Gertz describes going straight to a regimen that lowers the protein quickly, and for myeloma names bortezomib-based triplets as the fastest.
Evidence: Review opinion drawing on response-time data from treatment trials: "For patients who have hyperviscosity, an indication for therapy, and no symptoms, rapid-acting systemic chemotherapy can reduce the serum viscosity and obviate the need for plasma exchange." The 2023 international workshop panel states the shared principle of reducing tumour and abnormal protein burden rapidly and deeply; its full report was not read.
Blood (Gertz, Mayo Clinic; narrative review, the author declares personal fees from drug companies outside the work) 2018 · Seminars in Hematology (Buske et al.) 2023
Rituximab can push the abnormal IgM protein up for a few weeks before bringing it down, which can thicken the blood when the level is already high. Hospitals prevent this differently: plasma exchange first, leaving rituximab out of the first cycles, or watching closely. No study has compared them, and the two guidelines that recommend acting grade their evidence as low.
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Therapeutic plasma exchange for symptomatic hyperviscosity in hypergammaglobulinaemia “Symptomatic HVS is a potentially life‐threatening medical emergency.” | Category I, Grade 1B | American Society for Apheresis (Journal of Clinical Apheresis, Zantek et al.) 2026 |
| Therapeutic plasma exchange as prophylaxis before rituximab “Therefore, in patients with serum viscosity > 3.5 cp or IgM level > 4 g/dL, TPE should be considered prior to rituximab.” | Category I, Grade 1C | American Society for Apheresis (Journal of Clinical Apheresis, Zantek et al.) 2026 |
| What ASFA category I means “Disorders for which apheresis is accepted as first‐line therapy, either as a primary standalone treatment or in conjunction with other modes of treatment.” | Category I | American Society for Apheresis (Journal of Clinical Apheresis, Zantek et al.) 2026 |
| Hyperviscosity is an emergency, an indication for plasma exchange and an indication for definitive treatment “This is also an indication for definitive treatment” | Grade A1 | British Society for Haematology (British Journal of Haematology, Pratt, El-Sharkawi et al.) 2022 |
| Defer rituximab or perform prophylactic plasmapheresis when IgM or M-protein is above 40 g/L | Grade C1 | British Society for Haematology (British Journal of Haematology, Pratt, El-Sharkawi et al.) 2022 |
| Monitor IgM, symptoms and plasma viscosity in everyone given rituximab | Grade A1 | British Society for Haematology (British Journal of Haematology, Pratt, El-Sharkawi et al.) 2022 |
| Start plasma exchange promptly for hyperviscosity syndrome, before cytoreductive therapy “Therapeutic plasma exchange should be promptly initiated for hyperviscosity syndrome, prior to commencement of cytoreductive therapy” | level 3, grade B | JAMA Oncology (Kapoor et al., Mayo Clinic; read as the author manuscript on PubMed Central, supplement not read) 2017 |
| Rituximab alone is contraindicated in symptomatic hyperviscosity and, without pre-emptive plasmapheresis, best avoided at a very high IgM “Rituximab monotherapy is contraindicated in patients with symptomatic hyperviscosity, and, without preemptive plasmapheresis, is best avoided in patients with very high serum IgM” | level 3, grade A | JAMA Oncology (Kapoor et al., Mayo Clinic; read as the author manuscript on PubMed Central, supplement not read) 2017 |
| A single-volume exchange lowers the paraprotein by about 40%, and 1 to 3 procedures are usually needed “Single-volume plasma exchange will reduce the paraprotein by approximately 40%. It usually takes 1–3 procedures for symptoms and viscosity to reduce.” | ungraded text | British Society for Haematology (British Journal of Haematology, Pratt, El-Sharkawi et al.) 2022 |
| Consider hyperviscosity when viscosity is above 3 mPas “approximately half of 85 patients with symptomatic HVS had a serum viscosity less that 4 mPas and so it should be considered if greater than 3 mPas” | ungraded text | British Society for Haematology (British Journal of Haematology, Pratt, El-Sharkawi et al.) 2022 |
| Each exchange lowers viscosity by 20% to 30%, so about 1 to 2 are needed for IgM “Each TPE reduces viscosity by 20%–30%. Therefore, only about 1–2 TPE are needed.” | ungraded text | American Society for Apheresis (Journal of Clinical Apheresis, Zantek et al.) 2026 |
| IgM returns to baseline about 3 to 5 weeks after exchange “After about 3–5 weeks following TPE, serum IgM levels return to baseline.” | ungraded text | American Society for Apheresis (Journal of Clinical Apheresis, Zantek et al.) 2026 |
| Withholding red cell transfusion in stable patients until viscosity is normal has no trial evidence “Although there is no scientific proof, there is a theoretical argument that could be made to withhold transfusion in hemodynamically stable patients until serum viscosity is normalized in order to avoid the rheological impact of adding red cells to the circulation.” | ungraded (narrative review) | Blood (Gertz, Mayo Clinic; narrative review, the author declares personal fees from drug companies outside the work) 2018 |
| Retinal signs can be present without visual symptoms and are a reason to treat “Epistaxis is a common presenting symptom, and if present in a patient with a possible paraproteinemia, should prompt additional evaluation for HVS, particularly fundoscopic examination, as evidence of ocular HVS can be present without visual symptoms and is a treatment indication.” | ungraded (narrative review) | Frontiers in Oncology (Weaver, Rubinstein and Cornell; narrative review) 2020 |
| Fundoscopy for anyone with suspected hyperviscosity or a serum IgM above 3 g/dL “Due to the high prevalence of ophthalmologic manifestations of HVS, a fundoscopic examination should be performed in any patient with suspected HVS or with a serum IgM > 3 g/dL.” | ungraded (narrative review) | Frontiers in Oncology (Weaver, Rubinstein and Cornell; narrative review) 2020 |
| Add rituximab only once IgM is below 4,000 mg/dL “However, given the risk of rituximab induced IgM flare, the addition of rituximab is recommended only when the serum IgM level is <4,000 mg/dL.” | ungraded (narrative review) | Frontiers in Oncology (Weaver, Rubinstein and Cornell; narrative review) 2020 |
| Severe adverse events with plasma exchange: 1.0% in a European registry of over 7,000 patients “In general, TPE is a safe procedure, with a severe adverse event rate of 1.0% in a European registry study of over 7,000 patients undergoing filtration-based exchange” | ungraded (narrative review) | Frontiers in Oncology (Weaver, Rubinstein and Cornell; narrative review) 2020 |
Shares M-protein, immunofixation and serum free light chains, Waldenström macroglobulinaemia, Multiple myeloma.
Shares M-protein, immunofixation and serum free light chains, Multiple myeloma.
Shares M-protein, immunofixation and serum free light chains, Multiple myeloma.